Drug Trial Radar · NCT07718737
Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
512
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Mar 30, 2028
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Multitude Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial consists of two parts: phase 2 and phase 3. The goal of phase 2 of this clinical trial is to compare which dose level of AMT-116 works better to treat advanced or metastatic non-squamous EGFR-Wildtype non-small cell lung cancer (NSCLC) in adults. It will also learn about the safety of AMT-116. The main questions it aims to answer are: * Which level of AMT-116 works better to treat advanced or metastatic non-squamous EGFR-Wildtype NSCLC? * What medical problems do participants have when taking AMT-116? The goal of phase 3 of this clinical trial is to compare AMT-116 to study doctor's choice (a kind of retainable treatment for you in the opinion of the study doctor) to see if AMT-116 works better to treat advanced or metastatic non-squamous EGFR-Wildtype NSCLC. In both parts of this trial, participants will receive AMT-116 or study doctor's choice every 2 weeks until the study doctor thinks you are benefiting from your participation or until your disease progresses or you are unable to tolerate the study drug
Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
AMT-116Drug
AMT-116 will be administered at 4 mg/kg or 5 mg/kg as an intravenous (IV) infusion on Day 1 of each 2-week cycle.
Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab)Drug
Docetaxel will be administered as an IV infusion of 75 mg/m2 over approximately 60 minutes on Day 1 of each 3-week cycle. Ramucirumab will be administered as an IV infusion of 10 mg/kg over 30-60 minutes on Day 1 of each 3-week cycle prior to docetaxel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events as Assessed by CTCAE v6.0Time frame: About 7 months
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida · Not yet recruiting
Lumi Research
Kingwood, Texas · Not yet recruiting
Coffs Harbour Health Campus
Coffs Harbour, Australia · Not yet recruiting
Austin Health (Olivia Newton John Cancer Centre)
Melbourne, Australia · Not yet recruiting
St Vincent's Hospital Melbourne
Melbourne, Australia · Not yet recruiting
Calvary Mater Newcastle
Newcastle, Australia · Not yet recruiting
Macquarie University Hospital
Sydney, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.